Fresenius Kabi
Pierre Langlade has extensive experience in regulatory affairs and quality management, currently serving as the Senior Vice President of Regulatory Affairs & Quality ELAMA at Fresenius Kabi since January 2011. Prior to this role, Pierre held the position of Vice President of Regulatory Affairs at Fresenius Kabi ELAMA after serving as ELAMA RA Director between 2005 and January 2011. Pierre began a career in regulatory affairs at Baxter, where responsibilities included being Clintec RA Manager from 1998 to 2005. Educational background includes studies at Externat Sainte Marie La Verpillière, Université Claude Bernard Lyon 1, and école Pont de Cheruy.
This person is not in any teams
This person is not in any offices
Fresenius Kabi
16 followers
Fresenius Kabi is a global healthcare company that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition. Our products and services are used to help care for critically and chronically ill patients. Fresenius Kabi’s product portfolio comprises a comprehensive range of I.V. generic drugs, infusion therapies and clinical nutrition products as well as the devices for administering these products. In the field of biosimilars, Fresenius Kabi focuses on autoimmune diseases and oncology. In 2019, the first biosimilar product by Fresenius Kabi was launched. Within transfusion medicine and cell therapies, Fresenius Kabi offers products for collection of blood components and extracorporeal therapies.